10:39:55 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-06 Bokslutskommuniké 2024
2024-11-14 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-06-07 X-dag ordinarie utdelning EXPRS2 0.00 SEK
2024-06-05 Årsstämma 2024
2024-05-16 Kvartalsrapport 2024-Q1
2024-02-08 Bokslutskommuniké 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-25 X-dag ordinarie utdelning EXPRS2 0.00 SEK
2023-05-24 Årsstämma 2023
2023-05-16 Kvartalsrapport 2023-Q1
2023-03-23 Extra Bolagsstämma 2023
2023-02-09 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-31 Kvartalsrapport 2022-Q1
2022-05-27 X-dag ordinarie utdelning EXPRS2 0.00 SEK
2022-05-25 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-27 X-dag ordinarie utdelning EXPRS2 0.00 SEK
2021-05-26 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-09-23 Extra Bolagsstämma 2020
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-27 X-dag ordinarie utdelning EXPRS2 0.00 SEK
2020-05-26 Årsstämma 2020
2020-05-20 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-24 X-dag ordinarie utdelning EXPRS2 0.00 SEK
2019-05-23 Årsstämma 2019
2019-05-16 Kvartalsrapport 2019-Q1
2019-02-28 Bokslutskommuniké 2018
2018-11-22 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-25 X-dag ordinarie utdelning EXPRS2 0.00 SEK
2018-05-24 Årsstämma 2018
2018-05-17 Kvartalsrapport 2018-Q1
2018-02-07 Bokslutskommuniké 2017
2017-11-30 Kvartalsrapport 2017-Q3
2017-08-31 Kvartalsrapport 2017-Q2
2017-06-01 X-dag ordinarie utdelning EXPRS2 0.00 SEK
2017-05-31 Årsstämma 2017
2017-05-24 Kvartalsrapport 2017-Q1
2017-04-19 Extra Bolagsstämma 2017
2017-02-28 Bokslutskommuniké 2016
2016-11-08 Kvartalsrapport 2016-Q3
2016-08-31 Kvartalsrapport 2016-Q2

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
ExpreS2ion Biotech Holding är ett forsknings- och utvecklingsbaserat bolag med en patenterad plattform inom bioteknisk proteinproduktion. Bolaget har sin egen utvecklingspipeline av vaccinkandidater inom COVID-19, bröstcancer, influensa och malaria. Dessutom har bolaget intäkter från försäljning av tillverkningstjänster och plattformslicenser. Bolaget startade 2010 och har sin verksamhet i DTU Forskerpark i Hørsholm.
2020-08-19 15:45:24

Hørsholm, Denmark, August 19, 2020 - ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") hereby updates the market on its expectations to the development timelines of the COVID-19 vaccine prior to the release of the Company's Q2 2002 report. The Company now expects the phase III trials to commence as soon as the first half of 2021, with possible market launch before the end of 2021.

The Company previously announced that the PREVENT-nCoV consortium, in which the Company is a partner, plans to enter the first clinical Phase I/IIa trial before the end of 2020, with headline results announced towards the end of Q1, 2021. The first trial will test the vaccine's safety as well as surrogate markers of efficacy (immune response). The Company now further announces that it expects the vaccine to enter phase III trials in the first half of 2021. If so, the vaccine could be ready for market launch already by the end of 2021. These milestones reflect current plans and expectations and are subject to the Company's development partners receiving the funding needed to carry out a 20-30.000 patient trial in the next few months, and not least, approval from the regulatory authorities.

ExpreS[2]ion's CEO Bent Frandsen comments:

"The pandemic itself, and the search for vaccines, continues to evolve. Last week saw the EU placing the first advanced purchase order for 300 million doses of the viral vector vaccine that AstraZeneca and Oxford University has in phase II/III development. We can expect to see a lot more of these types of announcements over the coming months, and a lot of additional funding being awarded. If all goes well, ExpreS[2]ion could see significant cash flows from COVID-19 vaccine sales starting within the next 12-18 months. Our expectation is that well over half a billion doses of our vaccine will eventually be needed over the next four to five years. This number could increase if the virus becomes endemic. Which sadly, it very well might."

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: ca@skmg.se